Long-term Complete Response in a Patient with Liver Metastases from Breast Cancer Treated with Metronomic Chemotherapy. Issue 3 (May 2014)

• Record Type: Journal Article
• Authors: Cecconetto, Lorenzo; Gardini, Andrea Casadei; Tenti, Elena; Maltoni, Roberta; Bravaccini, Sara; Oboldi, Devil; Zoli, Wainer; Serra, Patrizia; Donati, Caterina; Sarti, Samanta; Amadori, Dino; Rocca, Andrea
• Is Part Of: Tumori. Volume 100:Issue 3(2014)
• Page Start: 79
• Page End: 82
• Publication Date: 2014-05
• Subjects: long-term complete response -- metronomic chemotherapy -- breast cancer; Cancer -- Periodicals; 616.994
• DOI: 10.1700/1578.17238
• Languages: English
• ISSNs: 0300-8916

Abstract

Background: Preclinical studies have shown that several chemotherapeutic agents at low doses may affect the vascular system. Here we report the case of a patient with long-term cancer control by metronomic chemotherapy. Case Presentation: A 62-year-old woman with breast cancer underwent a left mastectomy in July 2007. For a liver metastasis she was given first-line chemotherapy with doxorubicin plus paclitaxel every 21 days. A CT scan after the sixth cycle showed a partial response. It was decided to stop the treatment with doxorubicin and paclitaxel, and start metronomic therapy with cyclophosphamide 50 mg daily orally and methotrexate 2.5 mg twice daily, 2 days a week. After 6 months of this maintenance treatment, CT scan showed a complete response. We examined the expression of vascular endothelial growth factor receptor 2 (VEGFR2) in histological sections of the primary tumor of our patient, finding evidence of overexpression of the receptor. The metronomic treatment is still ongoing, and after 60 months the patient maintains a complete response. Conclusion: This clinical case highlights how suitable metronomic chemotherapy can be used as maintenance therapy, allowing long-term treatment with no significant toxicity. This case suggests that the level of VEGFR2 is predictive of best response to antiangiogenic therapy.